| Sep 4 |
Ascendis Pharma Slashes Its Outlook Amid Pricing Fiasco, Sacrifices A Breakout
|
| Sep 4 |
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
|
| Sep 4 |
Ascendis Pharma GAAP EPS of -€1.91, revenue of €36M; revises FY24 revenue outlook
|
| Sep 4 |
Ascendis Pharma A/S (ASND) Q2 2024 Earnings Call Transcript
|
| Sep 3 |
Ascendis and Royalty Pharma enter into $150M royalty funding agreement
|
| Sep 3 |
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
|
| Sep 3 |
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
|
| Sep 3 |
Ascendis Pharma Reports Second Quarter 2024 Financial Results
|
| Sep 2 |
Ascendis Pharma Q2 2024 Earnings Preview
|
| Aug 29 |
Exploring Three High Growth Tech Stocks In The United States
|
